When was Avadel Pharmaceuticals founded?

Avadel Pharmaceuticals was founded in 1990 and raised its 1st funding round 28 years after it was founded.

Where is Avadel Pharmaceuticals located?

Avadel Pharmaceuticals is headquartered in Dublin, Ireland. It is registered at Chesterfield, Missouri.

Who is the current CEO of Avadel Pharmaceuticals?

Gregory J Divis of Avadel Pharmaceuticals.

How many employees does Avadel Pharmaceuticals have?

As of Apr 30, 2026, the latest employee count at Avadel Pharmaceuticals is 174.

Is Avadel Pharmaceuticals a funded company?

Avadel Pharmaceuticals is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Mar 02, 2018.

How much is Avadel Pharmaceuticals worth?

The last known valuation of Avadel Pharmaceuticals was $***** as of Oct 22, 2025.

When was the latest funding round of Avadel Pharmaceuticals?

Avadel Pharmaceuticals' latest funding was a $***** Post IPO round on Mar 09, 2022, with participation from 0 investor.

What is the annual revenue of Avadel Pharmaceuticals?

Annual revenue of Avadel Pharmaceuticals is $169M as on Dec 31, 2024.

Where does Avadel Pharmaceuticals rank among its competitors?

Avadel Pharmaceuticals ranks 13th amongst 1348 active competitors, of which 152 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Apnimed, which secured $50M in Apr, 2026.

Who are the top competitors of Avadel Pharmaceuticals?

Avadel Pharmaceuticals' top competitors include WuXi AppTec, ANI Pharmaceuticals and Apnimed. Among them, Apnimed secured the most recent funding round in April, 2026.

Avadel Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Avadel Pharmaceuticals is an acquired company based in Dublin (Ireland), founded in 1990. It operates as a Pharma company with proprietary drug delivery tools and drug for narcolepsy. Avadel Pharmaceuticals has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 1348 active competitors, including 152 funded and 169 that have exited. Its top competitors include companies like WuXi AppTec, ANI Pharmaceuticals and Apnimed.

Company Details

Pharma company with proprietary drug delivery tools and drugs for narcolepsy. The company is involved in the development of its lead candidate FT218, which is a once nightly formulation of sodium oxybate designed to treat narcolepsy sleeping disorder. The company is also involved in commercialized some hospital (mainly injectables) and pediatric (oral formulations) care products. The company offers 4 main drug delivery technologies - micropump (precisely delayed drug release microcapsules), liquitime (oral liquid formulation with delayed-release formulation), triggerlock (a mechanism to prevent abuse in opiate analgesics), and medusa (hydrogel depot formulation for subcutaneous injections).

Website: www.avadel.com
Social
Email ID: *****@avadel.com, *****@avadel.com
Phone Number: +353 **********
Registered Address: Chesterfield, Missouri

Key Metrics

Founded Year

1990

Location

Dublin, Ireland

Stage

Acquired

Latest Funding Round

Post IPO, Mar 09, 2022, $*****

Last Known Valuation

$***** as on Oct 22, 2025

Investors

RTW Investments & 5 more

Ranked

13^th among 1348 active competitors

Annual Revenue

$169M as on Dec 31, 2024

Employee Count

174 as on Apr 30, 2026

Investment & Acquisitions

Eclat Pharmaceuticals

Similar Companies

Apnimed & 355 more

Exit Details

Acquired by Alkermes (Oct 22, 2025)

View Avadel Pharmaceuticals' full profile

Avadel Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AVADEL PHARMACEUTICALS PLC CIN: 1012477 , United States, Active	Sep 22, 2003	$169M (As on Dec 31, 2024)	-	-
Avadel Pharmaceuticals Public Limited Company CIN: 572535 , Israel, Active	Jan 01, 1990	-	-	-
AVADEL US HOLDINGS, INC. CIN: 455225662 , United States, Active	Dec 26, 999	-	74 (As on Dec 31, 2018)	-

Avadel Pharmaceuticals got acquired by Alkermes on Oct 22, 2025 at an acquisition amount of $*****.

Click here to take a look at Avadel Pharmaceuticals's acquisition in detail

Avadel Pharmaceuticals has raised funding over 3 rounds. Its first funding round was on Mar 02, 2018. Avadel Pharmaceuticals has 6 institutional investors.

Here is the list of recent funding rounds of Avadel Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 09, 2022	8082701	Post IPO	3600696	2944180	8276412	7248422
Feb 21, 2020	4186015	Post IPO	3271962	3554885	3873137	Vivo Capital & 4 more
Mar 02, 2018	5302669	Conventional Debt	7822337	6854148	5566498	9951132

Access funding benchmarks and valuations. Sign up today!

View details of Avadel Pharmaceuticals's funding rounds and investors

Avadel Pharmaceuticals' employee count trend

Avadel Pharmaceuticals has 174 employees as of Apr 26. Here is Avadel Pharmaceuticals's employee count trend over the years:

Employee count trend for Avadel Pharmaceuticals

Uncover Avadel Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avadel Pharmaceuticals include WuXi AppTec, ANI Pharmaceuticals and Apnimed. Here is the list of Top 10 competitors of Avadel Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	79/100
2nd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	Ampersand Capital, US Bank & 4 others	64/100
3rd	Apnimed 2017, Cambridge (United States), Series C	Developer of small molecule based therapeutics for the treatment of obstructive sleep apnea	$249M	Morningside, Sectoral & 6 others	63/100
4th	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	ACE & Company, North Sky Capital & 2 others	63/100
5th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	63/100
6th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	63/100
7th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	62/100
8th	Aculys 2021, Fujisawa (Japan), Acquired	Developer of therapeutic medicines to treat neuropsychiatric disorders	$84M	SoftBank Vision Fund, Vision Pacific Life ... & 9 others	62/100
9th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	61/100
10th	Zuellig Pharma 1992, Singapore (Singapore), Funding Raised	Provider of clinical research, quality management, logistics, and clinical trial supply services	-	Temasek	61/100
13th	Avadel Pharmaceuticals 1990, Dublin (Ireland), Acquired	Pharma company with proprietary drug delivery tools and drug for narcolepsy	-	RTW Investments, Venrock & 4 others	59/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Avadel Pharmaceuticals's competitors? Click here to see the top ones

Avadel Pharmaceuticals has acquired Eclat Pharmaceuticals. Avadel Pharmaceuticals has not made any investments as of now.

Media has covered Avadel Pharmaceuticals for a total of 35 events in the last 1 year, 18 of them have been about company updates and 1 about partnerships.